Key facts
- cureVision’s last known valuation is $14.7M (Jan 2025).
- It has raised $2.6M; the latest was Later Stage VC in Sep 2025.
- Notable investors include European Innovation Council, NextCorps Luminate, Brandenburg Kapital, AQAL Capital, Angels4Health — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for cureVision
- ·The full record, as it builds
Funding rounds
No funding rounds for cureVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About cureVision
Developer of a wound analysis system designed to measure and analyze injuries. The company's platform measures the area, depth, and chronic wounds at the push of a button, recording other important healing parameters, enabling medical professionals to obtain automatic and precise analysis, as well as to track all parts of the body during movement.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2020
- Employees
- 22
- Website
- curevision.de/
- Ownership
- Privately Held (backing)
cureVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in cureVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on cureVision in its N-PORT filings yet. We sweep new filings monthly.